Signal transduction of c-Kit receptor tyrosine kinase in CHRF myeloid leukemia cells

Journal of Cancer Research and Clinical Oncology
Sebastian SchollReinhard Klinger

Abstract

The tyrosine kinase receptor c-Kit (stem cell factor receptor, CD117) is a potential target for signal transduction therapy in different cancers. In this study we investigated c-Kit in CHRF cells, a megakaryoblastic cell line of Acute Myeloid Leukemia (FAB M7). We characterized the interactions between c-Kit and PI 3-kinase (p85) after stimulation with SCF (stem cell factor) as well as the regulation of SHP-1 and SHP-2 associated with Kit in this cell line. Stimulation with SCF leads to a significant increase in interaction between Kit and p85 as well as in receptor associated PI 3-kinase activity. Interestingly, using different kinds of substances (AG 1295, CGP 53716) to inhibit the tyrosine kinase activity of c-Kit blocked activation of c-Kit, but the association of p85 still increased after SCF stimulation even when the tyrosine kinase activity of the receptor was completely blocked. In contrast, the other known interaction partners of c-Kit, SHP-1 and SHP-2, exhibited a basal association with c-Kit and no change of the association could be detected after stimulation of CHRF cells with SCF or treatment with the kinase inhibitors. Therefore, we suggest that association of p85, SHP-1, and SHP-2 to c-Kit in CHRF cells can, at l...Continue Reading

References

Mar 1, 1992·Proceedings of the National Academy of Sciences of the United States of America·M Z RatajczakA M Gewirtz
Oct 30, 1992·Cell·T Pawson, G D Gish
Apr 20, 1990·Cell·A Ullrich, J Schlessinger
May 24, 1994·Proceedings of the National Academy of Sciences of the United States of America·P PeraldiE Van Obberghen
Oct 15, 1993·Biochemical and Biophysical Research Communications·L BastienM Adam
Oct 1, 1995·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·H T Hassan, M Freund
Feb 16, 1996·The Journal of Biological Chemistry·M Kon-KozlowskiK A Siminovitch
Apr 1, 1996·In Vitro Cellular & Developmental Biology. Animal·B SandrockM A Lieberman
Apr 29, 1997·Proceedings of the National Academy of Sciences of the United States of America·B VanhaesebroeckM D Waterfield
Apr 5, 2001·The New England Journal of Medicine·B J DrukerC L Sawyers
Feb 26, 2003·Drugs·Katherine F Croom, Caroline M Perry
Jul 1, 1993·Current Biology : CB·T Pawson, J Schlessingert

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.

Cell Signaling by Tyrosine Kinases

Receptor tyrosine kinases (RTKs) are the high-affinity cell surface receptors for many polypeptide growth factors, cytokines, and hormones. RTKs have been shown not only to be key regulators of normal cellular processes but also to have a critical role in the development and progression of many types of cancer. Discover the latest research on cell signaling and RTK here.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.